Search results
Results from the WOW.Com Content Network
Cabotegravir in combination with rilpivirine is indicated for the treatment of human immunodeficiency virus type-1 (HIV-1) in adults. [1] [7] The combination injection is intended for maintenance treatment of adults who have undetectable HIV levels in the blood (viral load less than 50 copies/mL) with their current antiretroviral treatment, and when the virus has not developed resistance to ...
In 2012, the FDA approved the drug for use as pre-exposure prophylaxis (PrEP), based on growing evidence that the drug was safe and effective at preventing HIV in populations at increased risk of infection. [41] The FDA has approved two additional medications for PrEP since then, approving Descovy in 2019 and Cabotegravir (Apretude) in 2021. [4 ...
[4] [8] [9] It is the first FDA-approved injectable, complete regimen for HIV-infected adults that is administered once a month. [4] [5] It is also approved for use in Canada. [1] In the European Union, the two medications are approved separately and have different brand names: Vocabria (for cabotegravir) and Rekambys (for rilpivirine). [10 ...
Cabotegravir is recommended in combination with safer sexpractices for pre-exposure prophylaxis to reduce the risk of sexually-acquired HIV-1 infection in high-risk adults and adolescents weighing ...
"The purpose of PrEP is not to encourage risky behavior but to provide protection against HIV for individuals who are at higher risk of exposure." It's time we start talking about it. Anal sex is ...
The study seeks to test injectable PrEP as a way to remedy adherence for many patients on a daily pill regimen. [3] HPTN 083 is the first large scale phase III clinical trial of cabotegravir. [4] In February 2016 researchers presented the results of the ECLAIR study. [5] That study examined cabotegravir and found no serious safety concerns. [5]
Investigators interviewed more than 40 women who accused Tal, Oren and Alon Alexander of sex crimes. Alleged victims recounted the attacks in new footage released by prosecutors.
cabotegravir (brand names Apretude [as a single agent indicated for PrEP]; and Vocabria/Cabenuva [when co-administered with rilpivirine for HIV treatment – in partnership with Janssen Pharmaceuticals]) Protease inhibitors: fosamprenavir (brand names Lexiva and Telzir) nelfinavir (brand name Viracept) Entry inhibitors: